Is Beyond Air, Inc. (XAIR) a Buy, Sell, or Hold?
Beyond Air, Inc.
NASDAQ:XAIR
$5.77 USD
-$1.72 (-22.96%)
- Volume
- 108.24K
- Average Volume
- 332.74K
- Market Capitalization
- $3.66M
- P/E Ratio
- -0.07
- Dividend Yield
- 0.00%
- Price Target
- $1.00
- Year High
- $95.60
- Year Low
- $5.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.80
| Source | Headline |
|---|---|
|
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript seekingalpha.com - 2026-06-26 11:42:09 |
|
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 globenewswire.com - 2026-06-26 07:00:00 |
|
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day. globenewswire.com - 2026-06-22 16:01:00 |
|
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.Y. globenewswire.com - 2026-06-10 08:00:00 |
|
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p. m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N. globenewswire.com - 2026-06-10 08:00:00 |
|
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026. globenewswire.com - 2026-06-01 08:00:00 |
|
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection globenewswire.com - 2026-04-20 08:00:00 |
|
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York. globenewswire.com - 2026-04-15 08:00:00 |
